Hadasit Bio-Holdings Receives $7.2M Grant From Chief Scientist
Hadasit Bio-Holdings, the commercialization branch of Hadassah Medical Center based in Israel, has received NIS 25 million (approx. $7.2 million) from the Office of the Chief Scientist. The funds will be directed towards three of Hadasit’s portfolio companies: Cell Cure, KAHR Medical and Enlivex Therapeutics.
HBL focuses on funding the preparation for and execution of Phase I and preparation for Phase II by the portfolio companies. Preparations include pre-clinical trials, manufacturing, regulatory and business development tasks.